Evidence map›Paper›PMID 41293174›Full record

ArticleFrontiers in immunology2025

Reduced expression of UPF1 promotes tumor progression through stabilizing COX-2 mRNA in nasopharyngeal carcinoma.

Chun Wu, Ruowen Xiao, Lin Zhang, Zixuan Chen, Meiyin Zhang, Jiaxin Li, Yufeng Zhou, Shuocheng Wang, Chao Jiang, Huiyun Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chun Wu *State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Ruowen Xiao *Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Lin Zhang *Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Zixuan ChenDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.
Meiyin ZhangState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Jiaxin LiState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yufeng ZhouState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Shuocheng WangState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Chao JiangDepartment of Cancer Center, The People's Hospital of Shenzhen Baoan District, The Second Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Huiyun WangState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Rui SunDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.
Shijuan MaiState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: UPF1 (upframeshift 1) is the core factor in the nonsense-mediated mRNA decay (NMD) pathway. UPF1 is dysregulated in multiple human malignancies and may play a role in cancer progression. However, the expression level and function of UPF1 in nasopharyngeal carcinoma (NPC) have remained undocumented until now. Methods: UPF1 expression in NPC tissues was evaluated by using qRT-PCR and immunohistochemistry assays. Results: UPF1 expression was significantly downregulated in NPC tissues and correlated with a poor prognosis. UPF1 overexpression inhibited NPC cell growth and metastasis both Conclusions: Our findings suggest that reduced expression of UPF1 in NPC might contribute to tumor progression.

Indexed as

Cyclooxygenase 2Nasopharyngeal CarcinomaNasopharyngeal NeoplasmsRNA HelicasesRNA, MessengerTrans-ActivatorsAnimalsCell Line, TumorCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMiddle AgedCyclooxygenase 2PTGS2 protein, humanRNA HelicasesRNA, MessengerTrans-ActivatorsUPF1 protein, humancyclooxygenase-2macrophagenasopharyngeal carcinomanonsense-mediated mRNA decayup-frameshift 1

Identifiers

PMID41293174
PMCPMC12640816

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.